Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy

Hepatology Research

Volumn 40, Issue 9, 2010, Pages 870-877

  Kurosaki, Masayuki ^a   Hosokawa, Takanori ^a   Matsunaga, Kotaro ^a   Hirayama, Itsuko ^a   Tanaka, Tomohiro ^a   Sato, Mitsuaki ^a   Yasui, Yutaka ^a   Tamaki, Nobuharu ^a   Ueda, Ken ^a   Tsuchiya, Kaoru ^a   Kuzuya, Teiji ^a   Nakanishi, Hiroyuki ^a   Itakura, June ^a   Takahashi, Yuka ^a   Asahina, Yasuhiro ^a   Enomoto, Nobuyuki ^b   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Hepatocellular carcinoma; Interferon; Steatosis; Virological response

Indexed keywords

INTERFERON;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CANCER PATIENT; CANCER RISK; DISEASE ASSOCIATION; FATTY LIVER; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCREENING TEST; SEX DIFFERENCE; TREATMENT RESPONSE;

EID: 77956135578     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00692.x     Document Type: Article

References (31)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-76.
2. Shimada M, Hashimoto E, Taniai M. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002, 37:154-60.
3. Bugianesi E, Leone N, Vanni E. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-40.
4. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-54.
5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-38.
6. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004, 126:460-8.
7. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005, 54:533-9.
8. Yang S, Lin HZ, Hwang J, Chacko VP, Diehl AM. Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res 2001, 61:5016-23.
9. Lefkowitch JH, Schiff ER, Davis GL. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 1993, 104:595-603.
10. Kurosaki M, Matsunaga K, Hirayama I. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol 2008, 48:736-42.
11. Hourigan LF, Macdonald GA, Purdie D. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999, 29:1215-19.
12. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33:1358-64.
13. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002, 37:837-42.
14. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005, 41:82-7.
15. Leandro G, Mangia A, Hui J. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006, 130:1636-42.
16. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007, 22(1):S108-11. Suppl
17. Ohata K, Hamasaki K, Toriyama K. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97:3036-43.
18. Pekow JR, Bhan AK, Zheng H, Chung RT. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007, 109:2490-6.
19. Kumar D, Farrell GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol 2005, 20:1395-400.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996, 24:289-93.
21. Romero-Gomez M, Castellano-Megias VM, Grande L. Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol 2003, 98:1135-41.
22. Ramani K, Yang H, Xia M, Ara AI, Mato JM, Lu SC. Leptin's mitogenic effect in human liver cancer cells requires induction of both methionine adenosyltransferase 2A and 2beta. Hepatology 2008, 47:521-31.
23. Okuda M, Li K, Beard MR. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366-75.
24. Cai D, Yuan M, Frantz DF. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005, 11:183-90.
25. Arkan MC, Hevener AL, Greten FR. IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 2005, 11:191-8.
26. Moriya K, Fujie H, Shintani Y. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998, 4:1065-7.
27. Hickman IJ, Clouston AD, Macdonald GA. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002, 51:89-94.
28. Belfort R, Harrison SA, Brown K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-307.
29. Yoshida H, Shiratori Y, Moriyama M. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999, 131:174-81.
30. Nishiguchi S, Shiomi S, Nakatani S. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001, 357:196-7.
31. Shiratori Y, Ito Y, Yokosuka O. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005, 142:105-14.